TY - JOUR
T1 - Uptake of the nitroimidazole drug megazol by African trypanosomes
AU - Barrett, Michael P.
AU - Fairlamb, Alan H.
AU - Rousseau, Bernard
AU - Chauvière, Gerard
AU - Perié, Jacques
N1 - Funding Information:
M.P.B. and A.H.F. are grateful to the Wellcome Trust for their financial support. M.P.B. is also grateful to the Sir Halley Stewart Trust for financial support and to Marie-Pierre Hasne for providing trypanosomes.
PY - 2000/3/15
Y1 - 2000/3/15
N2 - Megazol, CL 64,855 (2-amino-5-[1-methyl-5-nitro-2-imidazolyl]-1,3,4-thiazole) has been shown to be extremely effective in clearing experimental infections of African trypanosomes. An unusual amino-purine transporter termed P2, implicated in the transport of both the diamidine and melaminophenyl arsenical classes of drug in Trypanosoma brucei, recognised chemical groups on compounds which are also present on megazol. Megazol interacted with this carrier protein, as judged by its ability to inhibit P2 adenosine transport and to abrogate in vitro arsenical-induced lysis in a dose-dependent manner. However, parasites resistant to melaminophenyl arsenical and diamidine drugs due to lack of the P2 transporter showed no resistance to megazol. This is because passive diffusion represented the major route of entry. Initial rates of uptake were not saturable within the limit of megazol's solubility and did not conform to thermodynamic precepts compatible with carrier-mediated uptake. Adenosine and other P2 transporter substrates, even at high concentration, had little impact on megazol uptake. Uptake was biphasic, with a very rapid equilibration across the membrane followed by a slower accumulation over time. The equilibration phase represented a simple passive diffusion, with the subsequent uptake probably being due to metabolism of the drug. Copyright (C) 2000 Elsevier Science Inc.
AB - Megazol, CL 64,855 (2-amino-5-[1-methyl-5-nitro-2-imidazolyl]-1,3,4-thiazole) has been shown to be extremely effective in clearing experimental infections of African trypanosomes. An unusual amino-purine transporter termed P2, implicated in the transport of both the diamidine and melaminophenyl arsenical classes of drug in Trypanosoma brucei, recognised chemical groups on compounds which are also present on megazol. Megazol interacted with this carrier protein, as judged by its ability to inhibit P2 adenosine transport and to abrogate in vitro arsenical-induced lysis in a dose-dependent manner. However, parasites resistant to melaminophenyl arsenical and diamidine drugs due to lack of the P2 transporter showed no resistance to megazol. This is because passive diffusion represented the major route of entry. Initial rates of uptake were not saturable within the limit of megazol's solubility and did not conform to thermodynamic precepts compatible with carrier-mediated uptake. Adenosine and other P2 transporter substrates, even at high concentration, had little impact on megazol uptake. Uptake was biphasic, with a very rapid equilibration across the membrane followed by a slower accumulation over time. The equilibration phase represented a simple passive diffusion, with the subsequent uptake probably being due to metabolism of the drug. Copyright (C) 2000 Elsevier Science Inc.
KW - Chemotherapy
KW - Drug uptake
KW - Megazol
KW - Sleeping sickness
KW - Trypanosomiasis
UR - http://www.scopus.com/inward/record.url?scp=0033952123&partnerID=8YFLogxK
U2 - 10.1016/S0006-2952(99)00368-8
DO - 10.1016/S0006-2952(99)00368-8
M3 - Article
C2 - 10677577
AN - SCOPUS:0033952123
SN - 0006-2952
VL - 59
SP - 615
EP - 620
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 6
ER -